Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634933 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT00634933 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 222 participants.
The verdict
NCT00634933, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of two dosing regimens of a compound known as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid arthritis.
Interventions
- DRUG Prednisone
- DRUG Methylprednisolone
- DRUG TRU-015
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00634933
The ClinicalTrials.gov registry entry for NCT00634933 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT00634933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00634933 about?
NCT00634933 is a clinical study titled "Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis". This study will evaluate the efficacy and safety of two dosing regimens of a compound known as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid arthritis.
What is the current status of trial NCT00634933?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2008-03. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00634933?
The interventions under investigation include: Prednisone (DRUG), Methylprednisolone (DRUG), TRU-015 (DRUG).
Who is sponsoring clinical trial NCT00634933?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.